Q4 08 Earnings Call. Kevin Hrusovsky President & CEO. March 12, 2009

Size: px

Start display at page:

Download "Q4 08 Earnings Call. Kevin Hrusovsky President & CEO. March 12, 2009"

Camron Atkins
5 years ago
Views:

1 Q4 08 Earnings Call Kevin Hrusovsky President & CEO March 12,

2 Agenda Highlights Strategic Roadmap Growth by SBU 2008 and 2009 Q4 08 and Q1 09 Growth Catalysts Value Creation Catalysts 2009 Guidance and Key Milestones 2

3 Substantially Improved outlook with enhanced balance sheet, top line growth, cost reductions, recurring revenue and patent protection Significant Q4 momentum with completed divestitures and sharpened SBU focus Achieved $36.7 M Q4 08 revenue, at top end of guidance Delivered positive ebitda in Q4 08 for the second quarter in a row, despite eliminated earnings of divested businesses Enhanced balance sheet: Sep 08 Now - Total available cash $15M $35M - Net cash ($6M) $12M - Loan due date Jun 09 Nov 10 Launched IVIS Kinetic in second half 2008, strengthening IVIS leadership Strong growth in molecular application markets, led by new LabChip Gx with 26 Q4 placements and 70% growth to Q units placed in 2 nd half. Reduced costs $12M in 2008, lowering breakeven Ebitda from $155M to $138M 3

4 Strategy The Microfluidics Company - Instruments -Chips -IP The Applications Company - Drug development and molecular diagnostics - Molecular applications (plates, chips, animals) - Labchip and imaging platforms Assemble tool box of leading technologies for Research and Mdx Sharpen focus on molecular applications and recurring profitable growth 4

5 Strategic Transformation Assemble tool box of leading technologies for Research and Mdx $1B / 15 years DNA, RNA, Protein Cells Mice Tissue Human in vitro in vivo Research $57M 08 4% mkt growth Imaging $46M 08 12% mkt growth Services $20M 08 10% mkt growth 5

6 Revenue & EBITDA Outlook Historic and Projected Growth (GAAP) Revenue & EBITDA $Millions Assumptions Organic growth midpoint 5.5% 65% revenue patent protected 15% R&D investment Ebitda breakeven $138M Q1 - $133M yr end Approaching Ebitda breakeven $35M available cash Jan 09 Project $25M+ cash at year end E Contract & Licens e Total Revenue uf Contract & License EBITDA Revenue from Divested Operations Total Revenue E 6

7 Strategic Road Map Sharpen focus on molecular applications and recurring profitable growth Market Growth Rates 20% 15% 10% Imaging Market Expansion $46M 08 Expand New Diseases and Modalities Services Share Gain $20M 08 Molecular Applications Grow 5% Non Non Core Products (PDQ and and AT AT in in 2008) Shed Research Reconfigure $ % 0 $200 M $400 M $600 M $800 M $1 B+ Market Size 7

8 Strategic Transformation Sharpen focus on molecular applications and recurring profitable growth Initiative Impact Cost savings implemented in 08 and early 09 - Lease terminations - Restructuring - Other efficiencies Divested Two Non-Core Product Lines - PDQ - AutoTrace Additional opportunities for cost savings and small non-core product divestitures $12M Annual Savings $21M 180% Price Premium $35M available cash at year end Approach Ebitda breakeven and generate cash to fund in imaging, LabChip and mdx investment 8

9 Strategic Reconfiguration Enhance Growth and profitability through SBU focus 2008 GAAP SBU Growth Organic Growth Organic Growth Research Products -15% 4% 4% Imaging 17% 13% 10% Services -6% -6% 4% Total Revenue -5% 6% 6% Note: Organic growth percentages exclude PDQ, AutoTrace, deferred revenue adjustments in purchase accounting and 2007 one time license and contract revenues in microfluidics. It also excludes adjustments for expected/actual foreign exchange effects. 9

10 Strategic Reconfiguration Enhance Growth and profitability through SBU focus Q4 '08 Q1 '09 SBU Q4 '08 GAAP Organic Growth Organic Growth Research Products -14% -1% 10% Imaging -2% -1% 3% Services -8% -8% -18% Total Revenue -9% -2% 3% Note: Organic growth percentages exclude PDQ, AutoTrace, deferred revenue adjustments in purchase accounting and 2007 one time license and contract revenues in microfluidics. It also excludes adjustments for expected/actual foreign exchange effects. 10

11 Strategic Reconfiguration Enhance Growth and profitability through SBU focus SBU Offering 08-'09 Units 2009 Revenue Organic Revenue Growth Research Molecular LH Platforms Molecular LC Platforms Shed Non-core Products $4.5 M $5.5 M t.b.d. 75% 40% Imaging IVIS Platforms (incl. Kinetic) $30 M 12% Services EPA Pfizer Wyeth $3 M $2 M $1 M 200% 20% 50% Asia Molecular Application & IVIS $15 M 15% 11

12 Q4 & Q1 LabChip GX Purchases Customers purchasing LabChip for: Protein therapeutics (Antibody) labs Molecular biology laboratories University core facilities Molecular diagnostic reference laboratories Reagent manufacturers Contract manufacturing organizations National government laboratories Many companies acquiring multiple units Asia companies not represented (distribution) 12

13 March 11 th Cambridge Symposium 75 registered attendees Key highlights: LabChip GX highly touted in for protein PAT/QbD and molecular biology applications Process analytics for protein therapeutics is an attractive market with significant long term growth potential LabChip GX enables experiments in an afternoon that require a month using CE GX coupled with statistical DOE methods yields faster time to biomass production Sampling of attendees: 13

14 Strategic Transformation Sharpen focus on attractive applications and recurring profitable growth SBU Long-term Impact Research Imaging Plastic Chip LabChip NextGen Hand Held POC Dx New Modalities - R&D - Acquisition New economics - Game changing technology Expand into nextgen sequencing/sample Prep Assessing content / collabortion oppt's Market expansion (x-ray, CT, etc.) Leverage leadership position Services EPA, Other Pharma / BioTech Increase gross margin Capitalize on outsourcing trend Refine Channel Exploring Channel Alternatives Increase mkt penetration and grow Asia 14

15 Compelling Inflection Point Summary Caliper is streamlined and focused on three strategic business units Exciting next generation product portfolio 65% of revenue is IP protected and focused on robust markets / applications Strong top line outlook driven by Imaging, molecular applications in Research and EPA Anticipate positive Ebitda in the 2 nd half of 2009 and full year 2010 Enhanced balance sheet with $35M available cash Jan 1, 2009 with additional small opportunities to further shed product lines to fund organic and acquisitional growth Metrics: 2009 revenue guidance $125M - $129M (4-7% organic growth) Q1 09: $25M - $28M (midpoint is 3% organic growth) 15

2012 First-Half Review. Paris - September 5, 2012

2012 First-Half Review. Paris - September 5, 2012 2012 First-Half Review Paris - September 5, 2012 Disclaimer This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis.